Company intelligence / Profile preview
Lemonex Inc.
Seoul, Republic of Korealemonexbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Lemonex has completed a Phase 1 clinical trial for LEM-S401 (siRNA therapy) and received approval for a Phase 1 clinical trial of LEM-mR203 (mRNA vaccine for COVID-19) in July 2023. The company is evaluating the safety of the DegradaBALL® mRNA vaccine platform in a Phase I clinical study at Seoul National University Hospital.
- Therapeutic areas
- GastroenterologyOncologyDermatologyInfectious Diseases
- Modalities
- mRNA vaccinessiRNA therapeuticsRNA immunotherapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
CEPI (Coalition for Epidemic Preparedness Innovations)International Vaccine Institute (IVI)
Beyond the preview
Go deeper on Lemonex Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lemonex Inc..